This seems to have a limited scope even for Type 2s. In many/most diabetics, the pancreas is already running as fast as possible so this can't help.
Lovely if more time spent on prevention, however, there is no profit in that and that is what drives drug companies. Not very impressed that the company was sent back twice by the FDA for more study. Rush to market is never a good sign
Fitness Minutes: (166,625) Posts: 210,680 1/29/12 2:16 A
i don't know if the potential side effects risk would be worth it... and have they demonstrated whether or not this speeds the death of the insulin producing cells in the pancreas? not yet... i think i would feel like a guinea pig with this med...
Fitness Minutes: (2,090) Posts: 2,795 1/28/12 10:19 A
... A mere 5 units of Byetta put me in the ER with glucose levels in the 30's and falling--and eating glucose didn't work because it had paralyzed my stomach muscles so the glucose couldn't get to where I could absorb it! It took some powerful stuff called Regulan IV to keep me from total meltdown. I was told there could be convulsions, coma... yikes.
There's no way I'd go anywhere near this new stuff... Just how that is, y'know?
I wish they'd spend more time researching what CAUSES diabetes instead of spending so much time and money on controlling the symptoms... stimulating the pancreas when it's already in trouble doesn't make much sense to me.
"The real secret of success is enthusiasm..." thanks, Walter P. Chrysler. I believe it. That's what I want in my life--to give my imagination a chance, to live with energy and enthusiasm! P.S. I looked up enthusiasm, and it says the root words mean God within... interesting...!
Ralph Waldo Emerson said 'Life belongs to the energetic.' But you don't have to be frenetic and hyper--some energy is quiet and steady, like a heartbeat... and that works too! LOL
I found this in SP Health News Today....If this Works then, Gosh This is Great !!!!
Bydureon Approved for Type 2 Diabetes
A once-weekly injection
FRIDAY, Jan. 27 (HealthDay News) -- Bydureon (exenatide extended release), Amylin Pharmaceuticals' long-acting version of the diabetes drug Byetta, has been approved by the U.S. Food and Drug Administration.
The once-weekly injection will include a label warning that the drug caused certain thyroid tumors in rats, the Dow Jones news service reported. It's not known whether the drug causes such tumors in people, the label warning says. But the drug shouldn't be used by people with a family history of medullary thyroid carcinoma (a form of cancer), the warning continues.
Twice in 2010, the FDA declined approval of Bydureon, requesting additional studies and clinical information, Dow Jones reported.
Bydureon is a "glucagon-like peptide-1 (GLP-1) receptor," a class of medications that helps the body produce more insulin, which helps regulate blood sugar.
SparkPeople, SparkCoach, SparkPages, SparkPoints, SparkDiet, SparkAmerica, SparkRecipes, DailySpark, and other marks are trademarks of SparkPeople, Inc. All Rights Reserved. No portion of this website can be used without the permission of SparkPeople or its authorized affiliates.
SPARKPEOPLE is a registered trademark of SparkPeople, Inc. in the United States, European Union, Canada, and Australia. All rights reserved.